Irlanti - englanti - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - linezolid - film coated tablet - 600 milligram - other antibacterials

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - linezolid - film coated tablet - 600 milligram - other antibacterials - other antibacterials - nosocomial pneumonia community acquired pneumonia indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration.

Yhdistynyt kuningaskunta - englanti - myHealthbox

actavis group ptc ehf - linezolid - film-coated tablets - 600mg - other antibacterials - nosocomial pneumonia community acquired pneumonia linezolid is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms). linezolid is not active against infections caused by gram negative pathogens. specific therapy against gram negative organisms must be initiated concomitantly if a gram negative pathogen is documented or suspected.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

cipla (eu) limited - linezolid (form ii) - film coated tablet - 600 milligram - other antibacterials

Malta - englanti - Malta Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - linezolid - film-coated tablet - linezolid 600 mg - antibacterials for systemic use

Malta - englanti - Malta Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - linezolid - film-coated tablet - linezolid 600 mg - antibacterials for systemic use

Malta - englanti - Malta Medicines Authority

accord healthcare ltd - linezolid - film-coated tablet - linezolid 600 meq/ml - antibacterials for systemic use

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - linezolid - film-coated tablet - 600 milligram(s) - other antibacterials; linezolid

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

accord healthcare limited - linezolid (form iii) - film coated tablet - 600 milligram - linezolid - antibacterials for systemic use; other antibacterials - linezolid is indicated in adults for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. in determining whether linezolid is an appropriate treatment, the results of microbiological tests or information on the prevalence of resistance to antibacterial agents among gram positive bacteria should be taken into consideration. (see section 5.1 for the appropriate organisms).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.